Theracos

TheracosBio, a pharmaceutical company established in 2000 by Edward P. Amento, is focused on developing and commercializing therapeutics for prevalent diseases, with a primary emphasis on type 2 diabetes.

The company's flagship product is Brenzavvy (bexagliflozin), an orally administered sodium-glucose cotransporter 2 (SGLT2) inhibitor. The U.S. Food and Drug Administration (FDA) approved Brenzavvy in January 2023 for the treatment of adults with type 2 diabetes. This approval was a significant milestone for the company, positioning it as a competitor in the diabetes care market. Brenzavvy's mechanism of action involves reducing the reabsorption of glucose from the blood and increasing its excretion in the urine, thereby lowering blood sugar levels.

TheracosBio's business model is centered on providing affordable medications to improve public health outcomes. The company aims to increase access to its treatments through strategic partnerships. One such collaboration is with SmithRx, a pharmacy benefits manager, to include Brenzavvy in its formularies, making the drug more accessible to patients. By focusing on affordability, TheracosBio addresses a critical need in the management of chronic diseases like diabetes, which can impose a significant financial burden on patients.

The company operates in the pharmaceutical industry, a highly regulated and competitive market. Its target clients include adults diagnosed with type 2 diabetes, and it reaches them through healthcare providers and pharmacy benefit managers. TheracosBio generates revenue through the sale of its pharmaceutical products, with Brenzavvy being its main commercialized asset.

Keywords: pharmaceutical, diabetes, SGLT2 inhibitor, Brenzavvy, bexagliflozin, oral medication, chronic disease, drug development, healthcare, FDA approved